Labiotech.eu

News and Trends 31 Mar 2023

Ablaze Pharmaceuticals to develop first-in-class therapy for liver cancer in China

Ablaze Pharmaceuticals, a biotech company focused on developing targeted radiotherapy (TRT) to benefit cancer patients in China, is developing plans for a first-in-class novel peptide drug candidate against GPC3. The proprietary GPC3-targeting peptide is being licensed from RayzeBio. Upon in-license of product candidates by Ablaze from RayzeBio, Ablaze will be responsible for clinical development and […]

March 31, 2023 - 2 minutesmins - By Jim Cornall

News and Trends 31 Mar 2023

Destiny Pharma gel reduces nasal staph in surgery patients

Destiny Pharma has revealed data showing its drug reduced Staphylococcus aureus in the nasal passage of pre-op cardiac surgery patients. Destiny Pharma is a clinical stage biotechnology company focused on the development of novel medicines to prevent life threatening infections. The data was published in the journal Infection Control & Hospital Epidemiology. The paper was […]

March 31, 2023 - 3 minutesmins - By Jim Cornall

News and Trends 31 Mar 2023

Candidate found to inhibit malignant melanoma growth

Malignant melanoma is a relatively aggressive type of skin cancer. When detected early, it is usually treatable by surgical resection only, but metastases develop, often spreading to distant areas. Currently, tumor thickness and the presence of ulceration are some of the known prognostic factors used as indicators of melanoma. Therefore, the discovery of markers to […]

March 31, 2023 - 2 minutesmins - By Jim Cornall

News and Trends 31 Mar 2023

€260M fund addresses dementia investment shortfall

EQT Life Sciences has closed its inaugural LSP Dementia Fund, raising approximately €260 million ($283 million) in fee-generating assets under management, meeting the hard cap and surpassing the target fund size of €100 million ($108.9 million). The LSP Dementia Fund is dedicated to investing in companies that are developing breakthrough drug therapies and medical technologies […]

March 31, 2023 - 3 minutesmins - By Jim Cornall

In Depth 31 Mar 2023

How has the collapse of the Silicon Valley Bank affected the biotech industry?

When investors got wind of Silicon Valley Bank (SVB) being forced to sell its treasury bonds at a loss, owing in part to surging interest rates in the past year – a move by the Federal Reserve to counteract rising inflation – panic followed a bank run. And in a swift spur of events, the […]

March 31, 2023 - 8 minutesmins - By Roohi Mariam Peter

Podcast 31 Mar 2023

Beyond Biotech podcast 40: Antibody-drug conjugates

This episode of the podcast is an in-depth look at antibody drug conjugates (ADCs). Our guests are Dr Pini Tsukerman, chief scientific of Nectin Therapeutics, and Matthew Robinson, chief technology officer of Immunome. This episode of the podcast is sponsored by PHTA. Immunome Immunome’s Discovery Engine leverages the information stored in memory B cells to […]

March 31, 2023

News and Trends 30 Mar 2023

Vaccitech announces positive topline data for chronic hepatitis study

Vaccitech plc has announced positive topline final data from the HBV002 study, a phase 1b/2a clinical trial of VTP-300 in people with chronic hepatitis B (HBV) infection. Vaccitech is a clinical-stage biopharmaceutical company focused on the development of novel T cell immunotherapeutics to use the immune system to potentially treat and cure chronic infectious diseases, […]

March 30, 2023 - 3 minutesmins - By Jim Cornall

News and Trends 30 Mar 2023

Could new riboswitch make gene therapy safer?

Turning genes on and off as easily and predictably as flicking a switch could be a powerful tool in medicine and biotech. A type of technology called a riboswitch might be the key.The Okinawa Institute of Science and Technology (OIST) in Japan, in collaboration with Astellas Pharma Inc., has developed a new toolkit that uses […]

March 30, 2023 - 5 minutesmins - By Jim Cornall

News and Trends 30 Mar 2023

SR One closes biotech fund at $600M

SR One, a transatlantic life sciences investment firm, has announced the close of its second fund at more than $600 million, exceeding its target of $500 million. Fund II is the second fund since SR One spun out from GlaxoSmithKline (GSK) in 2020 to form a fully independent investment firm. The diverse investor base of […]

March 30, 2023 - 2 minutesmins - By Jim Cornall

News and Trends 29 Mar 2023

Pharming immunodeficiency drug given FDA approval

Pharming Group N.V. has announced that the US Food and Drug Administration (FDA) has approved Joenja (leniolisib) for the treatment of activated phosphoinositide 3-kinase delta (PI3Kδ) syndrome (APDS) in adult and pediatric patients 12 years of age and older. Pharming’s Joenja, an oral, selective PI3Kδ inhibitor, is the first and only treatment approved in the […]

March 29, 2023 - 4 minutesmins - By Jim Cornall

Best in Biotech 29 Mar 2023

5 hearing loss biotech companies you should know about

More than 1.5 billion people – nearly 20% of the world’s population – live with hearing loss globally, with 430 million suffering from disabling hearing loss. In this article, we take a look at five of the top hearing loss companies making efforts to reduce these figures. According to the World Health Organization (WHO), nearly […]

March 29, 2023 - 7 minutesmins - By Willow Shah-Neville

Inside Labiotech 28 Mar 2023

Noticed something different? Labiotech is getting a new look for 2023!

Hi there, dear readers! I know, it’s been a while since we posted “behind the scene” updates from Labiotech so I’m sure you’re curious to know what we’ve been cooking during the past few months. Well, the reason is simple, we’ve been working hard on a whole new design for the website! With this new […]

March 28, 2023 - 3 minutesmins - By Joachim Eeckhout

Knowledge hub

Categories

Illuminating biotech in the City of Light: Inside Paris’s thriving ecosystem

ASCO 2025: key highlights in cancer therapeutics

Approaches

Therapeutic areas

New report: Artificial intelligence and the future of antibody discovery

Stem cell therapy: a potential cure for hearing loss?

R&D

BD

World biotech leaders

Connect with decision-makers and researchers worldwide for collaborative opportunities

Company

Join Us

Subscribe to our newsletter

Advertise with us

Illuminating biotech in the City of Light: Inside Paris’s thriving ecosystem

ASCO 2025: key highlights in cancer therapeutics

New report: Artificial intelligence and the future of antibody discovery

Stem cell therapy: a potential cure for hearing loss?

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Ablaze Pharmaceuticals to develop first-in-class therapy for liver cancer in China

Destiny Pharma gel reduces nasal staph in surgery patients

Candidate found to inhibit malignant melanoma growth

€260M fund addresses dementia investment shortfall

How has the collapse of the Silicon Valley Bank affected the biotech industry?

Beyond Biotech podcast 40: Antibody-drug conjugates

Vaccitech announces positive topline data for chronic hepatitis study

Could new riboswitch make gene therapy safer?

SR One closes biotech fund at $600M

Pharming immunodeficiency drug given FDA approval

5 hearing loss biotech companies you should know about

Noticed something different? Labiotech is getting a new look for 2023!

Subscribe to our newsletter to get the latest biotech news!

Illuminating biotech in the City of Light: Inside Paris’s thriving ecosystem

ASCO 2025: key highlights in cancer therapeutics

New report: Artificial intelligence and the future of antibody discovery

Stem cell therapy: a potential cure for hearing loss?

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Illuminating biotech in the City of Light: Inside Paris’s thriving ecosystem

ASCO 2025: key highlights in cancer therapeutics

New report: Artificial intelligence and the future of antibody discovery

Stem cell therapy: a potential cure for hearing loss?

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Subscribe to our newsletter

Get the latest biotech news directly to your inbox!

Newsletter Signup - Footer

Subscribe to our newsletter to get the latest biotech news!